用纤溶酶原预防透明膜病。一项合作研究。
Prevention of hyaline membrane disease with plasminogen. A cooperative study.
作者信息
Ambrus C M, Choi T S, Cunnanan E, Eisenberg B, Staub H P, Weintraub D H, Courey N G, Patterson R J, Jockin H, Pickren J W, Bross I D, Jung O S, Ambrus J L
出版信息
JAMA. 1977 Apr 25;237(17):1837-41.
PMID:321823
Abstract
In a double-blind, randomized study, 500 premature infants were treated with plasminogen or placebo intravenously within 60 minutes of birth. There was a substantial decrease in severe clinical respiratory distress, death caused by hyaline membrane disease, and total mortality in the plasminogen-treated infants as compared to the controls.
摘要
在一项双盲随机研究中，500名早产婴儿在出生后60分钟内静脉注射纤溶酶原或安慰剂。与对照组相比，接受纤溶酶原治疗的婴儿严重临床呼吸窘迫、透明膜病导致的死亡及总死亡率均大幅降低。
Zotero 插件